To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Art of the SPAC: H&F’s MultiPlan underscores growth in capital instrument
PPD, another H&F portfolio company that provides outsourced pharma services, returned to the public markets in February at an initial EV of approximately $14bn.
